1-cyclopropyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid | 2167972-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-cyclopropyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
• 英文别名: 1-cyclopropyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid；1-cyclopropyl-3-(trifluoromethyl)pyrazole-4-carboxylic acid
• CAS: 2167972-13-4
• 化学式: C₈H₇F₃N₂O₂
• 分子量: 220.151
• InChiKey: OORDINJLCFLWOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  ethyl (Z)-2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 32.0h， 生成 1-cyclopropyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  组织蛋白酶L抑制剂

  摘要：

  本申请公开了多种化合物。该多种化合物能够抑制组织蛋白酶L(CatL)。本申请还公开了提供了包含至少一种这些化合物的组合物。本申请还提供了一种或多种CatL相关疾病的治疗或预防方法。该方法可包括将组合物施用于受试者。

  公开号：

  CN116589425A

文献信息

• PYRAZOLES AS 11-BETA-HSD-1
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1999114A2

  公开（公告）日：2008-12-10
• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20220332713A1

  公开（公告）日：2022-10-20

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.
• [EN] PYRAZOLES AS 11-BETA-HSD-1<br/>[FR] PYRAZOLES EN TANT QUE 11-BETA-HSD-1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2007107470A2

  公开（公告）日：2007-09-27

  [EN] Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
  [FR] La présente invention concerne des composés de formule (I) ainsi que des sels pharmaceutiquement acceptables de ceux-ci, les substituants étant tels que précisés dans la description. Lesdits composés et les compositions pharmaceutiques les contenant sont utiles pour le traitement de maladies telles que, par exemple, le diabète sucré de type II et le syndrome métabolique.
• [EN] MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020065613A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. and; Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.
• Cathepsin L inhibitors
  申请人：BIOFRONT THERAPEUTICS (BEIJING) CO., LTD.

  公开号：US11858905B1

  公开（公告）日：2024-01-02

  The present disclosure provides a plurality of the compounds. The compounds are capable of inhibiting Cathepsin L (CatL). A composition including at least one of these compounds is also provided. A method for treating or preventing one or more CatL-related diseases in a subject is further provided. The method may include administering the composition to the subject.